Integer Holdings Corporation Faces Class Action Lawsuit Over Securities Fraud, Stock Plummets 32.28%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy ITGR?
Source: PRnewswire
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Integer Holdings Corporation, alleging securities fraud and other unlawful business practices, with investors needing to apply by February 9, 2026, to become Lead Plaintiff to protect their interests.
- Earnings Guidance Cut: On October 23, 2025, Integer lowered its full-year guidance, projecting net sales growth of -2% to 2% for 2025 and organic sales growth of 0% to 4% for 2026, indicating signs of weak market demand.
- Severe Market Reaction: Following the earnings warning, Integer's stock price plummeted by $35.22, or 32.28%, closing at $73.89 on October 23, 2025, reflecting investor concerns over the company's future growth prospects.
- Poor Device Market Performance: Integer admitted that two of its electrophysiology devices had experienced slower than expected market adoption, with this weak demand trend expected to continue into 2026, potentially further impacting the company's overall performance and market confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to fall
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 86.440
Low
75.00
Averages
86.25
High
95.00
Current: 86.440
Low
75.00
Averages
86.25
High
95.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Integer Holdings VP Sells 825 Shares Amid Ongoing Liquidity Management
- Executive Trading Overview: On March 13, 2026, Integer Holdings' VP Tom Thomas sold 825 shares of common stock in an open-market transaction valued at approximately $70,000, leaving him with 4,381 shares worth about $364,000, indicating a routine liquidity management strategy rather than a shift in conviction.
- Transaction Proportion Analysis: This sale represented 15.85% of Thomas's direct holdings, reflecting a consistent trading pattern over the past year that aligns with liquidity management rather than signaling negative sentiment about the company's future.
- Company Financial Performance: Integer Holdings reported $1.85 billion in revenue for fiscal year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, driven primarily by strong growth in its cardio and vascular segments, despite a 28% decline in stock price over the past year.
- Market Outlook Consideration: While the insider sale appears routine, investors are more focused on whether Integer can convert consistent revenue growth into sustained margin expansion and balance sheet improvement, which will likely have a more significant impact on the company's future market performance.
See More
Integer Holdings Insider Sells Shares
- Insider Stock Sale: On March 13, 2026, Tom Thomas, VP of Integer Holdings, sold 825 shares of common stock for a total transaction value of $70,000, representing 15.85% of his direct holdings, indicating a liquidity management action by the executive.
- Transaction Context: The sale was executed via direct ownership without involving any indirect entities or derivative securities, suggesting that this move is routine rather than a shift in confidence, despite the company's stock declining about 28% over the past year.
- Financial Performance Overview: Integer reported approximately $1.85 billion in sales for full-year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, primarily driven by growth in its cardio and vascular segment through new product ramps and acquisitions.
- Future Outlook Challenges: Despite consistent revenue growth, the company's leverage remains elevated near 3.0 times EBITDA, with debt increasing to $1.185 billion, prompting investors to consider whether Integer can translate revenue growth into sustained margin expansion and balance sheet improvement.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes' motion to dismiss, allowing the securities fraud class action to proceed, indicating serious consideration of investor allegations that could lead to significant financial liabilities for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may undermine investor confidence.
- Shareholder Rights Protection: Shareholders who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting legal avenues available for affected investors to potentially reclaim losses.
- Potential Market Impact: As the lawsuit progresses and may result in liability for the company, investor confidence in ASP Isotopes could wane, negatively impacting its stock price and reflecting market concerns over corporate governance and transparency.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Artisan Small Cap Fund Q4 2025 Investor Letter Highlights
- Portfolio Performance: Artisan Small Cap Fund posted strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, demonstrating its ability to achieve positive results amid market volatility despite trailing for the full year.
- Exit from Integer Holdings: The fund exited its investment in Integer Holdings Corporation during Q4 due to unmet earnings growth expectations, revenue slowdown, and lack of margin improvement, compounded by a leadership transition that raised concerns about future profit cycles.
- Hedge Fund Holdings Shift: By the end of Q4 2025, 32 hedge funds held Integer Holdings, up from 24 in the previous quarter, indicating increased market interest, yet the fund believes that other AI stocks present greater upside potential.
- Market Environment Impact: The market in 2025 experienced frequent sentiment shifts influenced by U.S. politics, trade policy, and geopolitical tensions, yet the fund remains focused on identifying profit cycles at reasonable valuations to navigate future market challenges.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Integer Holdings VP Sells 825 Shares Amid Ongoing Liquidity Management
- Executive Trading Overview: On March 13, 2026, Integer Holdings' VP Tom Thomas sold 825 shares of common stock in an open-market transaction valued at approximately $70,000, leaving him with 4,381 shares worth about $364,000, indicating a routine liquidity management strategy rather than a shift in conviction.
- Transaction Proportion Analysis: This sale represented 15.85% of Thomas's direct holdings, reflecting a consistent trading pattern over the past year that aligns with liquidity management rather than signaling negative sentiment about the company's future.
- Company Financial Performance: Integer Holdings reported $1.85 billion in revenue for fiscal year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, driven primarily by strong growth in its cardio and vascular segments, despite a 28% decline in stock price over the past year.
- Market Outlook Consideration: While the insider sale appears routine, investors are more focused on whether Integer can convert consistent revenue growth into sustained margin expansion and balance sheet improvement, which will likely have a more significant impact on the company's future market performance.
See More
Integer Holdings Insider Sells Shares
- Insider Stock Sale: On March 13, 2026, Tom Thomas, VP of Integer Holdings, sold 825 shares of common stock for a total transaction value of $70,000, representing 15.85% of his direct holdings, indicating a liquidity management action by the executive.
- Transaction Context: The sale was executed via direct ownership without involving any indirect entities or derivative securities, suggesting that this move is routine rather than a shift in confidence, despite the company's stock declining about 28% over the past year.
- Financial Performance Overview: Integer reported approximately $1.85 billion in sales for full-year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, primarily driven by growth in its cardio and vascular segment through new product ramps and acquisitions.
- Future Outlook Challenges: Despite consistent revenue growth, the company's leverage remains elevated near 3.0 times EBITDA, with debt increasing to $1.185 billion, prompting investors to consider whether Integer can translate revenue growth into sustained margin expansion and balance sheet improvement.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes' motion to dismiss, allowing the securities fraud class action to proceed, indicating serious consideration of investor allegations that could lead to significant financial liabilities for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may undermine investor confidence.
- Shareholder Rights Protection: Shareholders who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting legal avenues available for affected investors to potentially reclaim losses.
- Potential Market Impact: As the lawsuit progresses and may result in liability for the company, investor confidence in ASP Isotopes could wane, negatively impacting its stock price and reflecting market concerns over corporate governance and transparency.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Artisan Small Cap Fund Q4 2025 Investor Letter Highlights
- Portfolio Performance: Artisan Small Cap Fund posted strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, demonstrating its ability to achieve positive results amid market volatility despite trailing for the full year.
- Exit from Integer Holdings: The fund exited its investment in Integer Holdings Corporation during Q4 due to unmet earnings growth expectations, revenue slowdown, and lack of margin improvement, compounded by a leadership transition that raised concerns about future profit cycles.
- Hedge Fund Holdings Shift: By the end of Q4 2025, 32 hedge funds held Integer Holdings, up from 24 in the previous quarter, indicating increased market interest, yet the fund believes that other AI stocks present greater upside potential.
- Market Environment Impact: The market in 2025 experienced frequent sentiment shifts influenced by U.S. politics, trade policy, and geopolitical tensions, yet the fund remains focused on identifying profit cycles at reasonable valuations to navigate future market challenges.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
